

\$1.5M secured in non-dilutive funding for manufacturing & platform optimisation

Investor Highlights:

- Over \$1.5 million secured in non-dilutive funding support for manufacturing scale-up and platform optimisation across Nexsen's rapid diagnostics platform
- Nexsen admitted as an industry partner to SAGE-Manufacturing, a five-year, ARC-funded national research centre led by Monash University, RMIT, Deakin University and CSIRO
- Project will apply advanced catalysis science to Nexsen's diagnostic platform, targeting improved detection sensitivity and performance across its test pipeline
- Nexsen to gain access to two full-time researchers embedded at the Company's Australian R&D facility, working directly with Nexsen's team
- More than eight times leverage on annual cash investment, with Nexsen accessing over \$1.5 million in support for a \$35,000 annual cash contribution
- Partnership supports Nexsen's 2026 priority to expand R&D capacity and manufacturing readiness through non-dilutive, capital-efficient collaborations

Nexsen Limited (ASX:NXN) ("Nexsen" or the "Company") is pleased to announce that it has secured \$1.5 million in non-dilutive funding support through its admission as an industry partner to the Australian Research Council (ARC) Industrial Transformation Training Centre for Sustainable and Green Economy Manufacturing (SAGE-Manufacturing).

The funding will support manufacturing scale-up and platform optimisation across Nexsen's proprietary rapid diagnostics platform, which is being developed to provide fast, trusted results for conditions that have traditionally relied on delayed laboratory testing.

Under the program, Nexsen will work with SAGE-Manufacturing and RMIT University to apply advanced catalysis science to its rapid diagnostics platform, with a focus on catalytic signal enhancement and scalable diagnostic device manufacturing. Specifically, the project will target potential improvements in detection sensitivity, reliability and performance consistency.

Nexsen will gain access to two full-time researchers who will be embedded at the Company's Australian R&D facility, working directly with Nexsen's scientific team to advance manufacturing and platform optimisation. The support is valued at more than \$1.5 million across the five-year program and will be delivered for an annual cash contribution of \$35,000 and \$35,000 in-kind, representing more than eight times leverage on the Company's annual cash investment.

The partnership directly supports Nexsen's 2026 priority to expand R&D capacity and manufacturing readiness through non-dilutive, capital-efficient collaborations. It also supports the Company's broader strategy to build scalable production capability for future commercial launch.

About SAGE-Manufacturing

SAGE-Manufacturing is the ARC Industrial Transformation Training Centre for Sustainable and Green Economy Manufacturing. The five-year, \$4.84 million national research centre is led by Monash University in collaboration with RMIT University, the University of Melbourne, Deakin University and CSIRO. The Centre is focused on advancing sustainable, circular and green manufacturing through cutting-edge catalysis science.

Catalysis is central to modern chemical manufacturing and is estimated to be involved in approximately 90% of commercially produced chemical products. SAGE-Manufacturing's research spans catalysis in the green circular economy, catalysis in bioprocessing and sustainable catalysts for energy applications.

Further information on SAGE-Manufacturing is available at sagem.org.au.

Nexsen's Executive Chairman, Reece O'Connell, commented:

"Our mission at Nexsen is to become a global leader in rapid diagnostics. Closing the gaps that exist today where clinicians are forced to make critical decisions without the tools they need. Every improvement we make to our platform brings us closer to that goal, and SAGE-Manufacturing gives us access to world-class researchers and some of Australia's leading scientific minds to keep pushing that standard further. Doing so through non-dilutive funding, at minimal cost to shareholders, while advancing our manufacturing capability at the same time - this is exactly the kind of partnership we said we would pursue in 2026, and we are pleased to be delivering on that commitment."

-ENDS-

ASX release authorised by the Board of Directors.

For more information, please contact:

Corporate Enquiries	Company Secretary
e: corporate@nexsen.bio	e: NXN@reignadvisory.com
w: www.nexsen.bio	p: 61 2 9174 5388
a: Suite 1005, 4 Bridge Street, Sydney NSW 2000, Australia	

About Nexsen Limited (ASX: NXN)

Nexsen is developing a suite of rapid point-of-care diagnostics designed to deliver lab-grade results for conditions that have traditionally depended on delayed laboratory testing. The company is focused on areas of significant unmet clinical need, where faster diagnosis can improve patient outcomes and reduce pressure on healthcare systems.

Nexsen's lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The Company is also developing rapid kidney function diagnostics for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

Forward Looking Statements Disclaimer

Forward looking statements are typically identified by the use of forward looking terminology such as 'aims', 'believes', 'expects', 'may', 'will', 'could', 'should', 'seeks', 'intends', 'estimates', 'plans', 'assumes', 'envisages', or the negative thereof or other words of similar meaning. Examples of such forward looking statements include, among others, statements or discussions regarding the Company's business, financial or investment strategies, regulatory and product rollout strategies, estimates of expenditure, present or future plans or events, prospects, growth, objectives for future operations and estimates. Such forward looking statements include matters that are not historical facts and are subject to a number of risks and uncertainties, many of which are beyond the Company's control and all of which are based on the Company's current beliefs, intentions or expectations about future events. Such statements are, by their nature, subject to a number of known and unknown risks, uncertainties, assumptions and other important factors that could cause actual results, performance or achievements to differ materially from any expected future results, performance or achievements expressed or implied, by the forward looking statement.

Neither the Company nor any person gives any representation, assurance or guarantee that the occurrence of the event expressed or implied in any forward looking statements in this document will actually occur and you are cautioned not to place undue reliance on such forward looking statements. Factors that might cause forward looking statements to differ materially from actual results, performance or achievements include, among other things, global economic conditions, economic conditions in jurisdictions in which the Company may operate or invest, credit markets, legislative fiscal and regulatory developments, the effects of continued volatility in markets and exchange rate fluctuations. The forward looking statements contained in this document speak only as of the date this document and each of the Company, respective directors, officers, employees, agents, representatives and/or advisers expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this document.

For personal use only